PTC Therapeutics (PTCT) – Investment Analysts’ Weekly Ratings Updates

by · The Cerbat Gem

PTC Therapeutics (NASDAQ: PTCT) recently received a number of ratings updates from brokerages and research firms:

  • 11/25/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/19/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/13/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/8/2025 – PTC Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
  • 11/5/2025 – PTC Therapeutics had its “hold” rating reaffirmed by analysts at Cowen Inc.
  • 11/5/2025 – PTC Therapeutics had its price target raised by analysts at The Goldman Sachs Group, Inc. from $44.00 to $50.00. They now have a “sell” rating on the stock.
  • 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Wells Fargo & Company from $73.00 to $93.00. They now have an “overweight” rating on the stock.
  • 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Barclays PLC from $46.00 to $68.00. They now have an “equal weight” rating on the stock.
  • 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Citigroup Inc. from $50.00 to $75.00. They now have a “neutral” rating on the stock.
  • 11/5/2025 – PTC Therapeutics had its price target raised by analysts at TD Cowen from $50.00 to $63.00. They now have a “hold” rating on the stock.
  • 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $70.00 to $82.00. They now have an “outperform” rating on the stock.
  • 10/28/2025 – PTC Therapeutics had its price target raised by analysts at Jefferies Financial Group Inc. from $63.00 to $77.00. They now have a “buy” rating on the stock.
  • 10/20/2025 – PTC Therapeutics is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $73.00 price target on the stock.
  • 10/8/2025 – PTC Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
  • 9/27/2025 – PTC Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, Director Emma Reeve sold 25,562 shares of PTC Therapeutics stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $65.96, for a total transaction of $1,686,069.52. Following the sale, the director owned 10,332 shares of the company’s stock, valued at $681,498.72. The trade was a 71.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Neil Gregory Almstead sold 71,928 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $83.44, for a total transaction of $6,001,672.32. Following the completion of the sale, the insider owned 100,625 shares of the company’s stock, valued at $8,396,150. This trade represents a 41.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 408,307 shares of company stock valued at $28,541,707 in the last 90 days. 5.50% of the stock is owned by company insiders.

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

See Also